Matrix scaffolding for stem cell guidance toward skeletal muscle tissue engineering by Claudia Fuoco et al.
REVIEW Open Access
Matrix scaffolding for stem cell guidance
toward skeletal muscle tissue engineering
Claudia Fuoco†, Lucia Lisa Petrilli†, Stefano Cannata and Cesare Gargioli*
Abstract
Extracellular matrix (ECM) is composed of many types of fibrous structural proteins and glycosaminoglycans. This
important cell component not only provides a support for cells but is also actively involved in cell-cell interaction,
proliferation, migration, and differentiation, representing, therefore, no longer only a mere static structural scaffold for
cells but rather a dynamic and versatile compartment. This aspect leads to the need for investigating new bio-inspired
scaffolds or biomaterials, able to mimic ECM in tissue engineering. This new field of research finds particular
employment in skeletal muscle tissue regeneration, due to the inability of this complex tissue to recover volumetric
muscle loss (VML), after severe injury. Usually, this is the result of traumatic incidents, tumor ablations, or pathological
states that lead to the destruction of a large amount of tissue, including connective tissue and basement membrane.
Therefore, skeletal muscle tissue engineering represents a valid alternative to overcome this problem.
Here, we described a series of natural and synthetic biomaterials employed as ECM mimics for their ability to recreate
the correct muscle stem cell niche, by promoting myogenic stem cell differentiation and so, positively affecting
muscle repair.
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Background
The human body possesses the ability to recover any
minor damage while, after an acute injury or an exten-
sive defect caused by disease, congenital malformations,
or surgical removal, it is much more arduous or even
impossible for the body to heal on its own. This is particu-
larly true for the skeletal muscle that has an endogenous
capability to recover injured tissue by activating a re-
sponse regeneration process that firstly involves mono-
nuclear resident inflammatory cells, such as mast cells
and macrophages. Activated by the necrotic myofiber rup-
ture and the consequent release of factors, mononuclear
resident inflammatory cells secrete several chemotactic
signals (i.e., tumor necrosis factor (TNF)-α and interleukin
(IL)-6) to recruit and activate other circulating inflamma-
tory cells, in particular neutrophils, to the damaged site
[1]. Neutrophils, in turn, recruit monocytes that, once in-
vaded the injured tissue, begin to differentiate in macro-
phages that phagocytize necrotic muscle fibers, thus
removing cellular debris. Macrophages can be divided into
two different subpopulations, M1 pro-inflammatory and
M2 pro-regenerative macrophages. The initial wave of the
M1s activates muscle progenitor cells while M2 macro-
phages stimulate their proliferation and differentiation
[1, 2]. In particular, the most important resident multipo-
tent stem cells are satellite cells [3, 4]. These normally qui-
escent cells, in response to damage, become active,
proliferate, and finally differentiate into myotubes that dir-
ectly participate in the muscle regeneration process by
fusing with the existing injured myofibers or by forming
new ones [5–7]. This is what commonly happens during
muscle regeneration; on the other hand, large damage is
unable to recover by satellite cells activation and differen-
tiation. Therefore, alternative strategies were developed to
regenerate injured skeletal muscle tissues or even to
stimulate muscular tissue self-healing ability, by generat-
ing a three-dimensional scaffold for grafting. This ap-
proach is based on the isolation and culture of myogenic
cells, engulfed on natural or synthetic 3D scaffolds acting
as the extracellular matrix (ECM), and already demon-
strated regulating different cell functions such as survival,
migration, proliferation, and differentiation [8, 9].* Correspondence: cesare.gargioli@uniroma2.it
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In this review, we will describe the importance of the
ECM in tissue engineering focusing on different natural
(i.e., chitosan, silk fibroin, alginate, and agarose) or syn-
thetic biomaterials (i.e., polylactic acid, polycaprolactone,
and polyurethanes) that can be used in skeletal muscle
engineering to generate 3D artificial tissue structures.
ECM as a key regulator for cellular activities
The ability to stimuli response is a distinctive character-
istic of our life. We are continuously influenced by our
surroundings, and from the single cell to the entire or-
ganism, we are able to interpret and adequately respond
to the different signals that we receive. The ECM has a
fundamental role for cell life: survival, motility, and com-
munication [8, 9]. The ECM is the non-cellular part,
present within all tissues and organs, stuffing the space
around the cells with its complex network of macromol-
ecules, arranged in a unique three-dimensional organiza-
tion, whose precise composition and structure varies
from tissue to tissue, according to its particular func-
tional need [8]. The ECM not only provides a mere
structural scaffold for cells, as has been considered for a
long time, but also contributes to cellular and organ-
level functions in an active manner. Its importance in
this direction is confirmed by the fact that ECM is
deregulated in many different types of diseases, such as
osteogenesis imperfecta and osteoporosis [10]. The ECM
active role is carried out by modulating many cellular
functions in different ways, likewise mechanical stimula-
tion, which is achieved through varying the degree of
stiffness of the matrix components, directly influencing
cell differentiation [11]. This was observed in mesenchy-
mal stem cells (MSCs) able to differentiate into different
lineages depending on the substrate stiffness on which
they were plated [12]. Moreover, the ECM, by binding
many soluble factors (i.e., Wnt proteins, bone morpho-
genetic proteins (BMPs)) with its components, can store
them, so regulating their availability and activity. Further-
more, its proteins can also interact with cell adhesion mol-
ecules, influencing the chemical and intracellular signaling
and even stem cell differentiation [10]. Therefore, through
different stimuli, the ECM affects many cellular processes
such as cell growth, adhesion, migration, differentiation,
and even gene expression remodeling, not only during the
developmental and homeostasis processes but also in
response to physiological stress or injury and disease
[8, 10]. Moreover, it is important to mention that the
ECM is even involved in cell death. In fact, a programmed
cell death mechanism, called anoikis, exists and is induced
by the detachment of cells from the ECM, therefore caus-
ing the loss of cell-matrix interactions [13]. Even if the
macroscopic arrangement of the ECM does not change
during these cell-matrix interactions, the ECM is dynam-
ically remodeled by cells, thanks to the activity of matrix-
degrading enzymes such as cathepsins, heparanase, hyal-
uronidases, and metalloproteases (MMPs), in normal tis-
sue turnover and in disease too [14].
The main composition of the ECM
There are a large variety of macromolecules that con-
tribute to the ECM structure and function, and they can
be primarily divided into different main groups: fibrous
ECM proteins, including collagen, elastin, fibronectin,
and laminin; proteoglycans (PGs), and glycosaminogly-
cans (GAGs) [8]. Collagen represents 30 % of the total
proteins in humans and is the most ubiquitous and
abundant ECM fibrous protein, designed to provide
strength and resiliency to tissues, and able to regulate
cell adhesion, chemotaxis, and migration, and to guide
tissue development [9, 15]. In a given tissue, collagen fi-
bers are generally a heterogeneous mix of different types,
even if type I collagen usually predominates, representing
the most abundant ECM protein in many adult tissues,
such as dermis, bone, and tendon [8, 16]. Collagen synthe-
sis and deposition is mainly related to the activity of fibro-
blasts. These interstitial cells, residing in the stroma or
recruited from neighboring tissue upon an injury, are able
to organize collagen fibrils into sheets by exerting tension
on the matrix, hence influencing the alignment of collagen
fibers [10, 17]. Collagen is correlated with elastin, another
ECM fibrous component and insoluble protein polymer,
synthesized from the precursor tropoelastin, a linear poly-
peptide of 60–70 kDa. Elastin, together with glycoprotein
microfibrils, makes up the elastic fibers of large structures
that supply rebound to tissues commonly subjected to re-
peated stretching forces, such as the lung, heart, large
elastic blood vessels, bladder, and elastic cartilage [8, 9].
Fibronectin (FN) is the third fibrous ECM molecule and
consists of a protein dimer, composed of two monomers
linked by a pair of disulfide bonds, ubiquitously present in
the ECMs of different cell types with a crucial role in the
ECM organization and then cell attachment and function
[9]. FN is involved in cell migration during development
and has also been related to different pathological condi-
tions, such as cardiovascular disease and tumor metastasis
[15, 18]. Laminins are high molecular weight heterotri-
meric proteins composed by an α-chain, a β-chain, and a
γ-chain, each of which is encoded by individual genes
[19]. Laminins interact with each other, with other ECM
molecules and also with resident cells influencing cell ad-
hesion, proliferation, migration, and differentiation, being
fundamental for the sustainment and the survival of the
tissue [8]. PGs form the basis of ECM structure order and
are characterized by a core protein covalently attached
with one or more, equal or different, chains of highly
negatively charged heteropolysaccharides, called GAGs,
such as chondroitin sulfate, dermatan sulfate, keratan sul-
fate, or hyaluronic acid [8]. PGs can interact with growth
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factors, cytokines, and chemokines, participating in differ-
ent cell functional processes, and with other ECM mole-
cules, thereby contributing to the assembly of the ECM
scaffold [8, 20].
Exploiting ECM task for tissue engineering
The involvement of the cell-ECM interactions, in physio-
logical conditions and during regeneration processes
induced by an injury or a disease, has been well docu-
mented and ascertained during these last two decades.
The pivotal role of the ECM led to the conceiving and
later the realization of functional substitutes for damaged
or diseased tissues or organs, exploiting precisely that in-
fluence which ECM exerts on cells and guiding the way to
an emerging field, namely tissue engineering. This new
interdisciplinary scientific approach, that fuses engineering
principles with biological ones, looks at reproducing neo-
organogenesis in order to generate functional ex-vivo liv-
ing tissue, combining stem cells and even growth factors
with appropriate natural and/or synthetic biomaterials
mimicking native ECMs [21]. To do so, biomaterials have
to reproduce the biological and mechanical properties of
ECMs shaming cell’s native microenvironment and pro-
viding a temporary 3D structure in which cells can adhere,
grow, differentiate, and organize themselves into a specific
spatial arrangement, that is to say, new tissue. Their “bio”-
characteristics, such as biocompatibility, biodegradability,
and bioresorbability, play a fundamental role, since they
have to provide their progressive replacement with newly
formed healthy tissue without inducing any inflammatory
responses that, on the contrary, could lead to rejection or
necrosis meantime ensuring the correct functional devel-
opment of the newly formed tissue [22]. In order to attain
this purpose, stem cells combined with ad hoc biomimetic
matrix scaffold can be guided to differentiate into the de-
sired cellular type, according to the necessity. This close
tie has been highlighted by early studies showing that
ECMs could influence in vivo stem cell differentiation and
also stemness maintenance, by creating a local microenvir-
onment, so called “niche,” in which stem cells are embed-
ded [15, 23].
Skeletal muscle tissue engineering hits and failures
Skeletal muscle tissue engineering is challenging being
formed by parallel aligned multinucleated syncytia, en-
closed in extracellular connective tissue, that have to be
reproduced to ensure the appropriate mechanical tissue
properties and then functionalities. Myofibers must be
vascularized, to guarantee an adequate oxygen supply
and transport of nutrients for cellular survival; moreover,
they must also be connected to the nervous system and
other host tissues, including tendons and neighboring
muscles. In looking at the ECM, each muscle fiber is
enclosed by the basal lamina, essential in guiding the
regenerative process, typical of the skeletal muscle. More-
over, the presence of sulfate GAGs, PGs, and type I colla-
gen also contribute to maintain the structural muscle
integrity [25]. Therefore, all the structural and functional
peculiarities mentioned above have to be considered for
skeletal muscle tissue engineering to succeed. The particu-
lar interest in building an artificial functional muscle, re-
plying the natural one, comes from the fact that the
skeletal muscle tissue has an endogenous ability to regen-
erate after a minor damage, mostly thanks to the activa-
tion of satellite cells [26]. If, however, severe damage
happens, the skeletal muscle tissue is unable to self-repair.
For this reason, injuries deriving from massive trauma
such as accidents, combat missions, surgical procedures
(i.e., aggressive tumor removal) or muscle devastating al-
terations (i.e., muscular dystrophies) can affect large vol-
umes of muscles leading to the well-known volumetric
muscle loss (VML). In the condition in which given the
fact that the muscular tissue is unable to regenerate, it is
irreversibly substituted by a non-contractile collagen fi-
brotic scar tissue with a consequent loss of the muscle
function [26–28]. A used standardized protocol, repre-
senting the best procedure for severe muscle injuries, fore-
casts the substitution of the wasted tissue with a surgically
removed uninjured muscle one, called “muscle flap”
[29–32]. Even if it is widely used, this autologous trans-
plant is very invasive and does not avoid the formation of
scar tissue [33, 34]. Moreover, the muscular wound size
restoration is limited by donor site availability, since skel-
etal muscle tissues and other approaches must be thought
for treatment of VML. The tissue engineering approach
for recovering skeletal muscle defects is based on two
classical strategies: in vitro and in vivo tissue engineering
[35, 36]. The first approach aims at developing mature
and functional artificial muscle structures by culturing
cells with myogenic potential into a biomimetic matrix
until the correct tissue to be implanted on the recipient is
formed [30]. On the other hand, the in vivo strategy is
based on transplanting cells, alone or in combination with
a biomaterial, to reproduce a local niche at the site of
damage in order to influence and promote muscle regen-
eration or reconstruction [30, 37]. A more innovative and
promising strategy for skeletal muscle tissue engineering
is the in situ approach that is based on the employment
of biomaterial as guidance for endogenous regeneration
of injured tissue [30]. In general, these three strategies,
although differing for benefits and limits, are connected
by the necessity to identify good new bio-inspired scaf-
folds that act as ECM, being able to respond to specific
requests such as 3D support, mechanical and physico-
chemical features supporting myogenic cell differenti-
ation, protecting them from damages induced by immune
responses and finally to stimulate vascularization and
innervation.
Fuoco et al. Journal of Orthopaedic Surgery and Research  (2016) 11:86 Page 3 of 8
ECMs in skeletal muscle tissue engineering
A variety of synthetic or natural biomimetic materials
were taken into consideration for skeletal muscle tissue
engineering with the overall goal of mimicking ECM key
properties. Initial muscle organoids were obtained and
parallel oriented by employing static stretch into matri-
gel and native or modified collagen scaffolds, while re-
cently, a more promising native decellularized ECM has
been introduced, containing matrix protein and growth
factors critical for tissue regeneration [38, 39].
Decellularized ECMs
In general, decellularized ECMs can be harvested from
natural mammalian tissue sources, thanks to the re-
moval of cells and DNA content from native ECM, car-
ried out by employing physicochemical agents, enzymes,
detergents, or even a combination of these [40]. These
procedures may in fact alter the ECM, compromising its
biochemical, mechanical, and structural hallmarks. Hence,
optimized decellularization protocols need to be generated
basing on the specific requisites. To this purpose, Qing
and collaborators proposed as an efficient decellulariza-
tion protocol the use of a rat skeletal muscle indicating
that the muscle must be subjected to an oscillatory treat-
ment at 4 °C with 1 % SDS for 72 h. They showed that the
obtained acellular matrices have an intact ECM with the
complete removal of muscle fibers [41]. On the other
hand, Gillies and colleagues showed that by employing
50 nM latrunculin B for 2 h at 37 °C, hypertonic saline so-
lution (0.6 M potassium chloride for 2 h and 1 M potas-
sium iodide for 2 h), and DNase I 1 kU/ml, it was possible
to decellularize the mouse tibialis anterior muscle without
altering its ECM composition or mechanical properties
[42]. Moreover, recently, it has been evaluated the effi-
ciency of enzyme-detergent methods on cell removal of
mouse latissimus dorsi (LD). Demonstrating that extensive
washing of the LD with a mixture of 0.1 % trypsin/0.01 %
EDTA for 24 h and 1%Triton X-100 for 1 week could be
useful to produce an intact matrix free of cells, showing
comparable biomechanical features with the native tissue
[43]. Very recently, Badylak’s group developed and charac-
terized the structure, composition and bioactivity, of a
perfusion-decellularized porcine rectus abdominis (RA)
bioscaffold (pM-ECM) showing the ability to support the
reconstruction of a partial-thickness abdominal wall alter-
ation in rats. The porcine RA muscle consists purely of
cells through continuous perfusion by using a series of
chemical and enzymatic treatments via the inferior epigas-
tric artery and vein in a perfusion bioreactor [44]. Decellu-
larized ECMs are considered an ideal candidate scaffold
for muscle recovery becoming innervated by the nervous
system of the host and to promote new muscle formation,
either by activating host cells or by permitting the vehicle
of myogenic cells to produce new tissue [45–47]. Some
examples of FDA-approved scaffolds are as follows: decel-
lularized ECMs from porcine small intestine submucosa
(SIS), human, porcine and bovine dermis, porcine urinary
bladder (UB), and different species pericardium and por-
cine heart valves [48]. The performances of decellularized
skeletal muscle ECM (DSM-ECM) implants have shown
encouraging results in the repair of skeletal muscle de-
fects. For example, when used in a rat model to rescue
hind-limb muscle damage, it was able to recover contract-
ile force measures up to 85 % of pre-injury levels [33].
Interestingly, promising observations were reported from
ECM-derived scaffolds, even when they were tested in hu-
man patients with muscular deficits carrying out a func-
tional amelioration in three fifths of treated cases [49]. In
particular, the ECM-derived scaffold in vivo implantation
seems to induce an immune host response that leads to
the scaffold degradation, during which the scaffold is re-
populated by host-derived mononuclear cells [50, 51]. The
degradation of the ECM-derived scaffolds has a positive
influence on tissue regeneration since it triggers the re-
lease of many bioactive molecules such as vascular endo-
thelial growth factor (VEGF), hepatocyte growth factor
(HGF), or insulin-like growth factor (IGF) that chemotac-
tically recruit a variety of cell types, including those
capable of myogenesis, to the scaffold implantation site
[24, 52–55]. It also seems that these factors directly pro-
mote the switch of macrophages from an M1 pro-
inflammatory phenotype to an M2 regenerating one [51,
56]. The latter, in combination with the secreted factors, is
involved in the activation of stem cells, such as satellite
cells, and other progenitor cells, promoting new tissue for-
mation, vascularization, and innervation [57–59].
Naturally derived ECMs
Other naturally derived molecules have been obtained
even from non-mammalian sources [51]. Among them,
we can find chitosan, silk fibroin, alginate, and agarose,
which are derived from crustacean shells, silkworm co-
coons, algae, and seaweed, respectively [60–62]. They
have been widely employed in skeletal muscle tissue en-
gineering because they show endogenous bioactive prop-
erties and can create complexes with carbohydrates to
form molecules, such as ECM heparan sulfate, able to
link growth factors [20] [63–68]. For example, alginate
has been found that stiffness between 13 and 45 kPa is
able to ameliorate myoblast proliferation and differenti-
ation, also promoting the release of a variety of growth
factors, such as HGF and VEGF, all important for skel-
etal muscle regeneration [69–73].
Synthetically produced ECMs
As mentioned before, the scientific community is even
studying the development of synthetic materials that,
compared with natural polymers, have the advantage
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that their mechanical and structural properties can be
customized with extreme precision according to the in-
dividual needs.
Shandalov and colleagues described a protocol for pro-
ducing a thick, well-vascularized tissue flap for recon-
struction of full thickness abdominal wall defects [71].
Scaffolds were created by mixing poly-L-lactic-acid (PLLA)
and polylactic-co-glycolic-acid (PLGA). In particular, a
5 % (w/v) polymer solution of each was prepared separ-
ately, by dissolving 0.5 g polymer in 10 ml chloroform.
The two polymers were put together in a 1:1 ratio, to
produce a PLLA/PLGA solution. NaCl was sifted to 212–
600 μm particles, and 0.4 g was spilled into Teflon cylin-
der molds and suspended in 0.24 ml PLLA/PLGA
solution. Subsequently, chloroform and salt were elimi-
nated, respectively, by evaporation and distilled water
washing. The scaffolds were lyophilized and the cells
(endothelial cells (ECs), myoblasts, and fibroblasts) sus-
pended in a 1:1 mixture of Matrigel: cell medium ratio
was seeded on top of the scaffold. It was cultured in vitro
for 10 days to permit the cells to self-assemble, and then,
the engineered tissue obtained was bended around the
mouse femoral AV veins for another 7 days and, by then
well vascularized, was implanted to recover a full thick-
ness abdominal defect [32]. The advantage to use material
like this is that they can be scaffolded in many configura-
tions and geometries such as meshes, foams, or hydrogels
and they can be even enriched with lithography tech-
niques to create nanoscale patterns which have been
demonstrated to improve myoblast alignment and differ-
entiation even in vitro and in vivo [51, 72, 73]. Another
important characteristic is that they can be functionalized
by chemical modification to improve their performances
in regeneration. Moreover, growth factors of other signal-
ing molecules can be incorporated in their bulk structure
with the same aim of improving regenerative outcomes.
Some promising hybrid materials also exist, such as
polyethylene glycol-fibrinogen (PEG-fibrinogen), a hybrid
innovative hydrogel formed by pegylated denatured fi-
brinogen molecules. In particular, the PEG allows to con-
trol the material features and the fibrinogen ensures
inherent bioactivity, including cell-adhesion motifs and
protease degradation sites [74]. This hydrogel has proven
applications in three-dimensional cell culture, in cardiac
cell therapy and tissue engineering [75]. The ability to
undergo controlled and localized liquid-to-solid transition
(gelation) in the presence of a cell suspension is one of the
main advantages of this biomaterial. This state change can
be done both in vitro and also in vivo, for example, inside
an injured muscle. Based on this property, we demon-
strated the ability of PEG-fibrinogen (PF) as cell carrier to
guide and improve the therapeutic effect of donor perivas-
cular myogenic progenitors (mesoangioblasts) [76]. More-
over, by using PF, we were also able to develop in vivo a
functional artificial muscle, by encapsulating mesoangio-
blasts in the bulk of the hydrogel that, once used to re-
place the mouse ablated tibialis anterior (TA), resulted in
a muscle tissue practically identical to a physiological one
with vascularization and innervation (Fig. 1) [77]. In par-
ticular, PF hydrogels were prepared at final concentration
of 8 mg/ml diluted with sterile PBS as required. To permit
gelation transition, the photo-initiator Igracure™ 2959 was
incorporated into PF mixture at the final concentration of
0.1 % w/v cells which were added at the desired concen-
tration, and 100 μl of the suspension was added into sili-
con molds and immediately exposed to UV light (365 nm,
4–5 mW/cm2) for 5 min. In experiments in which PF was
used as carrier, the suspension was conveyed by intra-
muscle injection and exposed to UV light (365 nm,
200 mW/cm2) using a hand-held light gun for 1 min to
allow the photopolymerization reaction. Even if we were
able to accurately recreate a vascularized and innervated
skeletal muscle, using an innovative methodology that
gives the possibility to develop and let mature directly in
Fig. 1 PF-embedded mesoangioblast grafted in an ablated TA lodge, showing full recovery of muscular morphology. a Surgical operation dislodging
mouse TA. b Mesoangioblasts (Mabs) embedded into PF hydrogel scaffold located in the TA lodge. c Gross morphology of the TA injury at 40 days
after massive muscle ablation, revealing the new artificial TA regeneration when grafted with PF-embedded Mabs
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vivo the artificially created skeletal muscle tissue, we were
still far from reaching human-sized tissue, since the scal-
ing up for human clinical therapeutic application repre-
sents a crucial goal.
Conclusions
Biomimetic scaffolds for skeletal muscle tissue engineer-
ing are developed considering the ECM not only an im-
plantable medium to vehicle cells and furnish them
structural support but also an inductive and bioactive
material, able to guide or even substitute endogenous
tissue regeneration process.
Here, we have reported some of the purposes and
challenges of creating biomimetic scaffolds to support
skeletal muscle regeneration after an extensive damage,
leading to VML. So, the different natural or synthetic
biomaterials described can be used in tissue regener-
ation, with or without modifications, and mimic the key
features of the natural ECM controlling different cell
processes such as cell-cell interaction, proliferation, mi-
gration, differentiation, cell survival, and even cell death.
To date, by using these new approaches, the complete
restoration of an extensive damage has not been reached
yet; nevertheless, it is evident that those represent a use-
ful instrument deserving further advancement perhaps
in combination with other engineering techniques as 3D
bio-printing.
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